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KAT6B sequence variants have been identiﬁed previously in both patients with the Say-Barber-Biesecker type of
blepharophimosis mental retardation syndromes (SBBS) and in the more severe genitopatellar syndrome (GPS). We report on the
ﬁndings in a previously unreported group of 57 individuals with suggestive features of SBBS or GPS. Likely causative variants
have been identiﬁed in 34/57 patients and were commonly located in the terminal exons of KAT6B. Of those where parental
samples could be tested, all occurred de novo. Thirty out of thirty-four had truncating variants, one had a missense variant and
the remaining three had the same synonymous change predicted to affect splicing. Variants in GPS tended to occur more
proximally to those in SBBS patients, and genotype/phenotype analysis demonstrated signiﬁcant clinical overlap between SBBS
and GPS. The de novo synonymous change seen in three patients with features of SBBS occurred more proximally in exon 16.
Statistical analysis of clinical features demonstrated that KAT6B variant-positive patients were more likely to display hypotonia,
feeding difﬁculties, long thumbs/great toes and dental, thyroid and patella abnormalities than KAT6B variant-negative patients.
The few reported patients with KAT6B haploinsufﬁciency had a much milder phenotype, though with some features overlapping
those of SBBS. We report the ﬁndings in a previously unreported patient with a deletion of the KAT6B gene to further delineate
the haploinsufﬁciency phenotype. The molecular mechanisms giving rise to the SBBS and GPS phenotypes are discussed.
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INTRODUCTION
The Say-Barber-Biesecker syndrome (SBBS, MIM 603736), also
referred to as the Say-Barber-Biesecker variant of Ohdo syndrome1
is a rare multiple congenital anomaly syndrome, which is usually
diagnosed clinically on the basis of a striking facial phenotype.
Typically, patients have a distinctive mask-like face with severe
blepharophimosis and ptosis, a broad nasal bridge, bulbous nasal
tip, small mouth, thin upper lip and small, low set ears. Long thumbs
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and long great toes may be present along with congenital heart defects,
thyroid abnormalities, hypoplastic teeth and absent or hypoplastic
patellae.2 Genital anomalies, usually cryptorchidism, are universally
present in males, and cleft palate has been observed in a number of
cases. All individuals with SBBS, reported so far, have had global
developmental delay and severe intellectual disability. Patients with
features overlapping those of SBBS were reported by Young and
Simpson3 in 1987, and it is now generally agreed that Young–Simpson
syndrome and SBBS are in fact the same entity. Young and Simpson
were the ﬁrst to draw attention to the presence of hypothyroidism
in this condition. Clayton-Smith et al4 identiﬁed KAT6B, a histone
acetyltransferase, as the causative gene for SBBS by a whole-exome
sequencing approach and reported sequence variants in 13 individuals.
Subsequently, Szakszon identiﬁed a further two SBBS individuals with
KAT6B sequence variants5 and another individual was reported
recently by Yu et al.6 In addition, KAT6B sequence variants have
been reported in 11 patients with genitopatellar syndrome (GPS, MIM
606170), a further multiple anomaly phenotype previously considered
to be quite distinct from SBBS.7,8 In GPS, the overall clinical picture
tends to be more severe than in SBBS.9 The main diagnostic features
of GPS include the presence of large joint contractures, ambiguous
genitalia and absent patellae. Agenesis of the corpus callosum,
hydronephrosis and congenital heart disease are frequently present,
and thyroid abnormalities have been reported in rare cases. The facial
phenotype of GPS has not been well described but is not considered so
distinctive as in SBBS, with the diagnosis usually being made based on
the other clinical features.
To further delineate the clinical and molecular spectrum of KAT6B,
we have studied a new cohort of 57 patients with a clinical diagnosis of
SBBS (n= 47), GPS (n= 5) or features overlapping both of these
entities (n= 5). We have gathered detailed clinical information on this
group and screened for sequence variants in the coding exons of
KAT6B by Sanger sequencing. Our study aimed to deﬁne differences
in clinical features between KAT6B variant-positive and KAT6B
variant-negative patients, and to explore the breadth of the phenotypic
spectrum, examining in particular, the clinical overlap between SBBS
and GPS.
PATIENTS AND METHODS
Ascertainment of study patients
In 2011, we ascertained a cohort of 19 patients with SBBS for genetic studies
and identiﬁed likely pathogenic KAT6B sequence variants in 13 of these.4
For this current study, we have gathered a cohort of a further 57 patients with
features suggestive of SBBS or GPS who were recruited via clinical geneticists
from within the UK or abroad. Forty-ﬁve patients were tested for KAT6B
sequence variants as part of a research study, exploring the genetic basis of
blepharophimosis syndromes (REC reference 10/H1016/12). Variants in a
further nine patients were identiﬁed in the diagnostic laboratory within the
Manchester Centre for Genomic Medicine. Three further individuals (23, 24,
25) were referred to our study after KAT6B variants had been identiﬁed in
laboratories in Ulm (2) and Freiburg (1). Individuals 23 and 24 had originally
been ascertained as part of a study of the UBE3B gene,10 but were considered to
have features more suggestive of a KAT6B phenotype. Referring clinicians
provided detailed phenotypic information and photographs of participants for
review. Consent to publish clinical details was obtained from all participating
families and consent to publish photographs was obtained for those included in
this report.
Sequencing of KAT6B
Samples from the 54 individuals studied in Manchester were screened for
sequence variants in all 18 exons of KAT6B by Sanger sequencing. Details of
primer design and synthesis are given in Supplementary Information Table 1.
The coding exons and the intron–exon boundaries of KAT6B were ampliﬁed by
polymerase chain reaction. Post-PCR puriﬁcation was conducted to remove
unwanted reaction components using the Agencourt AMpure XP (Beckman
Coulter Genomics, Takeley, UK) system on a Biomek NX Liquid Handler
(Beckman Coulter). The puriﬁed PCR products were then subjected to
sequencing using BigDye Terminator v3.1 (Invitrogen, Paisley, UK). Reactions
were puriﬁed using Agencourt CleanSEQ solution (Beckman Coulter) by
Beckman Coulter NX robotics. Automated capillary electrophoresis was
conducted on the ABI 3730XL Genetic Analyzer (Applied Biosystems, Paisley,
UK) using POP-7 polymer (Life Technologies, Paisley, UK) according to local
protocols. The reference sequence of KAT6B NG_032048.1, covering transcript
NM_012330.3 was uploaded as a txt.ﬁle to Staden package Pregap4 1.4b1. The
sequence data were aligned and analysed graphically using the DNA sequence
analysis software, STADEN (http://staden.sourceforge.net/). Any variants iden-
tiﬁed were checked against the NCBI SNP database (dbSNP, http://www.ncbi.
nlm.nih.gov/SNP/) and against the Exome Variant Server (http://evs.gs.
washington.edu/EVS/) to distinguish common variants from likely pathogenic
variants. The variant interpretation software Alamut, (http://www.interactive-
biosoftware.com/software/alamut/features) was used to interpret and predict
the consequences of identiﬁed variants. Sequence variants identiﬁed were
reported according to the Human Genome Variation Society nomenclature.
Where available, DNA from the parents of the patients with possible pathogenic
variants was screened to investigate if the change was de novo. Three patients
(numbers 23, 24 and 25) were sequenced in other genetic laboratories as
reported above using similar methodology, but in cases 23 and 24, only exon 18
was sequenced. Taking into account the clinical context, that is, all patients had
Table 1 Genotype–phenotype differences between KAT6B-positive and KAT6B-negative patients
KAT6B+(n1=47) KAT6B− (n2=23)
Present Not present Not known Present Not present Not known P-value
Hypotonia 44 2 1 9 14 0 o0.0001
Feeding difﬁculties 42 3 2 15 8 0 0.0051
Contractures 27 7 13 6 12 5 0.0020
Dental anomalies 28 14 5 7 16 0 0.0087
Long thumbs 33 14 0 3 20 0 o0.0001
Long great toes 31 16 0 5 18 0 0.0008
Thyroid abnormalities 23 22 2 1 22 0 0.0001
Congenital heart defects 27 19 1 12 11 0 0.6177
Genital anomalies 25 22 0 7 15 1 0.1237
Abnormal patella 15 31 1 1 22 0 0.0134
Microcephaly 12 23 12 8 12 3 0.7734
Cleft palate 14 33 0 2 21 0 0.0690
Bold values indicate signiﬁcance (Po0.05).
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been selected on the basis of a clinical diagnosis of SBBS or GPS, sequence
variants were classiﬁed as causative or not. Variants resulting in a truncated
protein were classiﬁed as causative. Variants deemed to be likely causative were
missense changes, which were proven to be de novo, or if in silico analysis
predicted them to affect splicing or highly conserved amino acids. Sequence
changes that were synonymous and did not affect splicing, missense changes
reported in EVS or those seen in a parent were classiﬁed as being unlikely to
cause disease. Details of causative variants were submitted to the LOVD public
database at http://databases.lovd.nl/shared/genes/KAT6B, (patient IDS
00018483-00018515).
Genotype–phenotype analysis
Patients were classiﬁed as having either a SBBS phenotype (n= 47), a GPS
phenotype (n= 5) or an overlapping phenotype (n= 5) by dysmorphologists
from the Manchester Centre For Genomic Medicine on the basis of clinical
information and photographs. In accordance with previous literature, large
joint contractures, patellar abnormalities and ambiguous genitalia/severe genital
anomalies were considered as core features of GPS.9 For SBBS, the chracteristic
facial features of blepharophimosis and mask-like face were the key diagnostic
features. To analyse differences in phenotypic features between variant-positive
and variant-negative patients, we studied 45 variant-positive patients for whom
we had detailed clinical information (Supplementary Table 2a). This group
included the 13 patients, which we had reported previously.4 We compared
their clinical phenotypes with those of 23 variant-negative patients
(Supplementary Table 2b), including ﬁve reported previously (patients 71–75).4
Differences between the presence of 11 commonly presenting features in SBBS
and GPS were analysed using the Fisher’s Exact test. We noted the type and
position of the causative and likely causative variants within the SBBS group,
the GPS group and the group with the overlapping phenotype. Comparison was
also made with sequence data from 28 patients with KAT6B sequence variants
previously reported in the literature (11 GPS and 17 SBBS).
RESULTS
Sequence analysis
Sequencing of all 18 coding exons and intron–exon boundaries of
KAT6B in our new cohort of 57 patients identiﬁed 34 causative or
likely disease-causing KAT6B variants. Of these, 26/47 SBBS indivi-
duals had such variants, 4/5 GPS patients and 4/5 of those with an
overlapping phenotype. The majority (29/34) were truncating variants,
but one was a missense variant, one was a synonymous change shared
by three unrelated SBBS patients and one was an in-frame deletion.
The sequence variants are summarised in Supplementary Table 3,
which also incorporates the ﬁndings from our original cohort3 and
previous reports.4–6 In addition, we observed a recurrent sequence
variant, which we considered not causative of disease, consisting of a
12 bp sequence in exon 16 c. 3252_3263 p.(Glu1086_1089), which was
either deleted or duplicated. The majority of the causative sequence
variants identiﬁed clustered at the C-terminal end of the gene in exon
18, as documented previously. This exon encodes a highly conserved
serine- and methionine-rich transcriptional activation domain. How-
ever, we also identiﬁed variants that occurred more proximally in exon
18 and in exons 15, 16 and 17. Three individuals shared an identical
de novo synonymous variant in exon 16, c.3147 G4A p.(Pro1049Pro).
The Alamut 2.2 prediction programme suggested that this change was
likely to create a cryptic splice site. All three individuals had the typical
SBBS phenotype. One patient had a missense variant in exon 15,
c.2959 T4C p.(Trp987Arg). The parents of this patient were not
available for study, so the question as to whether this variant is
causative remains, but it has not been reported as a SNP on dbSNP,
and the amino acid 987 is well conserved. In silico analysis predicted
that this variant may be causative. In 18/34 cases where parental
samples could be tested, all of the sequence changes identiﬁed had
occurred de novo. Several of the variants were recurrent, having been
seen in more than one individual or reported previously in the
literature (see supplementary Table 3).
Genotype/phenotype correlation
The position of the variants in the GPS patients relative to the SBBS
patients is shown in Figure 1. In previously reported cases, the
sequence variants in GPS patients have tended to cluster more
proximally to those in SBBS.7,8 This was the case overall in our four
GPS patients who had variants in exon 17 and more proximally in
exon 18. However, we observed that patient 54 who had patellar
abnormalities, contractures, genital anomalies and agenesis of the
corpus callosum (all features, which overlap between GPS and SBB)
had the c.4205_4206del p.(Ser1402Cysfs*5) variant. This variant has
been reported in patients with typical SBBS4 who lacked the features of
large joint contractures, agenesis of the corpus callosum and renal
anomalies, although one patient with this variant had patellar
abnormalities. The variant occurs more distally to the other GPS
variants. Patient 56 whose sequence change occurred more proximally
in exon 18 had signiﬁcant genital anomalies and was also considered
to have an overlapping phenotype. The remaining two patients with
overlapping phenotypes (53 and 55) had the variants c.4320_4321del
p.(Lys1441Glyfs*23) and c.4074_4079del p.Glu1367_Glu1368. Patients
1 and 17 had truncating variants occurring more proximally to those
seen in GPS, yet they had a working diagnosis of SBBS and patient 20
who had one of the more proximal variants in exon 17 did not have
any abnormalities of the patellae, genitalia, kidneys or corpus
callosum. The three individuals (12,13,14) who all shared the same
exon 16 de novo synonymous variant ﬁtted better with SBBS, as all had
the typical facies, normal patellae, and none had signiﬁcant contrac-
tures, agenesis of the corpus callosum or renal anomalies. All of the
above observations suggest that the clinical distinction between GPS
and SBBS is not always clear, and it might be more important for the
clinician to recognise when a patient has clinical ﬁndings within the
broader KAT6B spectrum rather than to only consider the possibility
of a KAT6B phenotype if the clinical features ﬁt clearly within either
the GPS or SBBS entities. This broader presentation of a KAT6B
spectrum disorder was the basis upon which testing KAT6B was
suggested in case 51, a 24-week fetus with contractures, agenesis of the
corpus callosum and hydronephrosis.
Comparison of individuals with and without KAT6B sequence
variants
Comparison and analysis of clinical features from variant-positive and
variant-negative patients indicated that dysmorphic facial features, in
particular blepharophimosis, severe intellectual disability and devel-
opmental delay were common to both groups (Figure 2,
Supplementary Figure 1). Genital anomalies, usually cryptorchidism,
was universal in males with KAT6B sequence variants and tended to be
more severe in GPS, where the genitalia may be ambiguous. Genital
anomalies (hypoplastic labia) were noted in one affected female, but
we suspect that genital anomalies in females are under-ascertained.
Signiﬁcant features, which predicted whether a pathogenic KAT6B
variant would be found, were the presence of hypotonia, thyroid
abnormalities, patellar abnormalities, long thumbs and great toes,
feeding difﬁculties and dental anomalies. A pathogenic KAT6B
sequence variant was much more likely to be identiﬁed if the latter
features were present (Table 1). The commonest cardiac anomalies
observed in the KAT6B-positive group were atrial and ventricular
septal defects and patent ductus arteriosus, though one patient had a
Tetralogy of Fallot, and right-sided aorta and pulmonary stenosis were
seen in several patients. Dental anomalies, particularly hypoplastic
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teeth, emphasised as a salient feature of SBBS in the early literature,
were reported as present in only 21/44 individuals with KAT6B
variants though they were a signiﬁcant distinguishing feature. Hearing
loss, often remarked upon in the early literature on SBBS was present
in around a third of individuals with likely pathogenic KAT6B variants
and was usually sensori-neural in origin. Cleft palate was seen in 14/44
patients, drawing attention to the fact that SBBS and GPS deserve
consideration as a differential diagnosis for syndromic clefting.
Thyroid abnormalities were present in 22/42 KAT6B-positive patients
where these had been searched for and only 1/22 KAT6B-negative
patients, again making this one of the most important distinguishing
features. The commonest abnormality was congenital hypothyroidism,
with raised TSH. Thyroid agenesis was also documented in some
patients. There was considerable clinical overlap between the clinical
features of the SBBS and the GPS patients. Blepharophimosis was less
striking in GPS (Figure 3) though this group did still have a distinctive,
but less obvious facial phenotype. Several patients with SBBS had
either agenesis of the corpus callosum, hydronephrosis and joint
contractures, features more typical of GPS. In SBBS, the joint
contractures were less severe and manifested more frequently as
talipes and overlapping ﬁngers and toes (Supplementary Figure 2)
rather than large joint contractures. Renal anomalies and agenesis of
the corpus callosum were probably under-ascertained in the SBBS
patients where MRI brain and renal scans had not always been
undertaken. Several GPS patients have had the long, straight thumbs
and great toes seen in SBBS, and this was even a feature in the fetus
observed at 24 weeks of gestation. An interesting observation was the
presence of malrotation of the bowel in two patients with KAT6B
sequence variants. A further patient had a laryngeal cleft. When
analysing the relationship between the position of KAT6B variants and
individual clinical features, no genotype/phenotype correlation could
be established. For patients with thyroid and patellar abnormalities, for
example, sequence changes were found across the region from exon 15
to the distal part of exon 18. The three patients who all shared the
same exon 16 synonymous change had a similar facial gestalt (Figure
2f–h), which had been easily recognisable as that of SBBS by their
referring geneticists, though ptosis was not as prominent in these three
patients as others with SBBS. All three had small, low set ears,
intellectual disability, global developmental delay, feeding abnormal-
ities and genital anomalies but lacked some of the other structural
malformations such as congenital heart defects, cleft palate and
patellar abnormalities.
DISCUSSION
This study conﬁrms previous ﬁndings that both SBBS and GPS are
caused by de novo truncating variants in KAT6B. However, it is clear
that not all variants are conﬁned to the terminal exon of this gene,
making it important to screen other exons, too, for diagnostic testing.
The study identiﬁed several novel splice site variants, including a
common synonymous variant in exon 16. Sequence changes causing
the more severe phenotype of GPS did appear overall to occur more
proximally as seen in the previous reports.5,6 Campeau et al11 have
hypothesised that features that occur commonly in both GPS and
SBBS are due to either haploinsufﬁciency or loss of a function
mediated by the C-terminal acidic domain, with the more severe
features seen in GPS being due to alterations in binding capacity of the
proteins arising as a result of speciﬁc GPS sequence variants. Our
results would partially conﬁrm these hypotheses, as they suggest that
the sequence variants cluster into three domains; (a) those occurring
more proximally, which are subject to nonsense-mediated decay
(NMD). The phenotype is a milder SBBS phenotype caused by
Gene
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Figure 1 Schematic representation of the spectrum of KAT6B variants
identiﬁed in this study. All coding exons are shown in purple. Arrows point
to the exonic location of the variants identiﬁed. Key: frameshift variants, in-
frame deletion, missense variant, synonymous variant, nonsense variants.
Variants identiﬁed in other studies are in italics. The protein structure shows
the protein domains. NEMM: highly conserved N-terminal domain with a role
in transcriptional repression. PHD: zinc ﬁnger domain, MYST: responsible for
histone acetyltransferase activity.
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haploinsufﬁciency. (b) Variants that are not subject to NMD but cause
a more severe GPS phenotype if they affect critical binding sites of
KAT6B. (c) variants that occur more distally and again escape NMD
but cause the SBBS phenotype rather than GPS, as they do not
interfere with the critical binding sites associated with GPS. All of these
three groups could share common features if, as Campeau suggest,
haploinsufﬁciency for the very distal C-terminal region is crucial, but
it is also possible that the more distal variants are also contributing to
a more severe SBBS phenotype due to a gain-of-function effect.
Further studies of the individual sequence variants are needed to
clarify the mechanisms involved. KAT6B deletions have been docu-
mented very rarely in the literature; Tzschach et al12 described four
patients with 10q22 deletions encompassing KAT6B. They had a mild
phenotype with common features of hypotonia and developmental
delay, especially in the area of speech. Facial features were nonspeciﬁc,
though on scrutiny of the available photographs, blepharophimosis
did appear to be a feature. Interestingly, one of the patients was noted
to have unusually long and straight thumbs. The DDD study
(DECIPHER@sanger.uk)13 identiﬁed a patient, DECIPHER number
258813, with a 2.5-Mb deletion encompassing KAT6B, HGVS
description chr10.hg19:g.75, 971,593_78,526,861del. This deletion
involved nine genes, of which KAT6B is the only one known to be
associated with a developmental disorder. This child, a male, weighed
2.1 kg at 37 weeks and presented with hypotonia and developmental
delay, particularly in the area of expressive speech. He had short
palpebral ﬁssures and prominent epicanthic folds (Figure 2e), but the
facial features were less striking than in SBBS. He had normal patellae
and a normal TSH level. He was macrocephalic and an MRI scan
showed only mild frontal atrophy. Thiel et al14 have previously
reported a patient with a translocation disrupting KAT6B and went
on to demonstrate that this individual had lowered the expression of
KAT6B. He had much milder features than patients with SBBS but did
have blepharophimosis and was reported as being ‘Noonan-like.’ Like
the patients reported by Tzschach and the DDD patient, there were no
major malformations present. The demonstration by Thiel et al that
RAS-MAP pathway gene expression was affected in this patient is
interesting in view of the fact that in two of our patients, a diagnosis of
Cardio-facio-cutaneous syndrome had been suggested initially and
Figure 3 Study patient 49 who shows typical features of genitopatellar syndrome. Note in 3a that blepharophimosis is less apparent, and in 3b the are knees
are held in ﬂexion and the patellae are displaced and hypoplastic.
Figure 2 2a, 2b, 2c, 2d show individuals 24, 20, 25 and 7 who all have sequence variants within KAT6B and show typical facial features of
blepharophimosis, mask-like face, small mouth and bulbous nose with depressed nasal tip. 2e shows the facial features of the boy with a large chromosome
deletion encompassing KAT6B, and who therefore has KAT6B haploinsufﬁciency. Individuals 2f, 2g, 2h are individuals 12, 14 and 13 who all have the
same de novo synonymous variant, predicted to affect splicing in exon 16 of KAT6B. 2i and 2j (cases 44 and 35) have blepharophimosis and intellectual
disability but neither have a KAT6B sequence variant and an alternative diagnosis is likely.
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that pulmonary stenosis and malrotation of the gut, both features seen
in RAS-MAP disorders were documented as clinical features in our
patient cohort. Only one convincing KAT6B sequence variant has been
seen in the proximal part of the gene (exon 3). This was documented
in the series by Clayton-Smith et al 4 in a patient with a much milder
blepharophimosis-intellectual disability phenotype. Taken together, all
of the above observations strengthen Campeau’s case that a mild
blepharophimosis-intellectual disability phenotype is caused by hap-
loinsufﬁciency of KAT6B ,whereas disease-causing variants toward the
terminal end interfere with the transcriptional activity of the gene, and
therefore cause a more severe phenotype through a gain-of-function
effect. These hypotheses remain to be tested in further studies.
From a clinical point of view, clinicians should be aware that the
KAT6B phenotypic spectrum is broad, encompassing presentations
from mild blepharophimosis and intellectual disability to the severe,
life threatening phenotype seen in GPS. Naming of the KAT6B-related
disorders has been problematic. Though it is possible to classify some
patients as having typical SBBS or GPS, this is not possible in all cases,
and we propose that considering this whole group as ‘KAT6B
spectrum disorders’ may be more helpful. Good diagnostic handles,
which might indicate a causative KAT6B sequence variant, include
severe blepharophimosis, patellar abnormalities, thyroid abnormalities,
hypothyroidism, long thumbs and toes and agenesis of the corpus
callosum. There are some similarities with RAS-MAP disorders, and
abnormalities of KAT6B may act in part by inﬂuencing this pathway.
The relatively broad clinical spectrum of KAT6B variants means that
clinical diagnosis is not always easy and suggests that affected
individuals might be identiﬁed in large-scale exome and genome
sequencing programmes rather than as a result of targeted testing.
Apart from one family, reported so far, where two affected siblings
were born to parents who did not carry the variant in blood, and
where gonadal mosaicism was presumed, all KAT6B variants have
occurred de novo and recurrence risks for most families are low,
though prenatal testing should be offered as an option.
No alternative diagnoses have yet been conﬁrmed in those patients
who did not have causative variants in KAT6B. On careful clinical
review, we considered that the majority of these had some atypical
features and that, rather than KAT6B variants or deletions being
missed, other diagnoses were more likely. A diagnosis of Cohen
syndrome was suggested in patient 57 based on the facial features and
additional ﬁnding of visual problems. Chromosomal abnormalities,
one of the main differential diagnoses, have been excluded by
microarray analysis. A further differential diagnosis, which was
excluded in suggestive cases, was that of a UBE3B phenotype.10
Verloes et al reviewed the classiﬁcation of the group of patients with
blepharophimosis-intellectual disability syndromes. He classiﬁed this
group into ﬁve main groups, including both SBBS and chromosomal
abnormalities. The remaining groups comprised the original patients
reported by Ohdo et al,15 The X-linked disorder originally reported by
Maat-Kievit et al16 and now known to be due to sequence variants
within the MED12 gene,17 and a recessive entity associated with
microcephaly and multiple structural anomalies. None of our patients
had features, which were consistent with any of these other groups
identiﬁed by Verloes. It is likely, therefore, that there are other causes
of blepharophimosis and intellectual disability, which remain to be
elucidated.
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